Patents by Inventor Connie Schmaljohn

Connie Schmaljohn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10493142
    Abstract: A synthetic, codon-optimized Hantaan virus (HTNV) full-length M gene open reading frame that consists of a unique nucleotide sequence encoding HTNV proteins. This synthetic gene was cloned into a plasmid to form the first optimized HTNV full-length M gene that elicits neutralizing antibodies in animals when delivered in combination with a similarly optimized Puumala virus (PUUV) DNA vaccine. The invention obviates the need for an extraneous gene sequence that was previously required for expression of the non-optimized HTNV gene. The synthetic gene is engineered into a molecular vaccine system to prevent hemorrhagic fever with renal syndrome (HFRS) caused by infection with HTNV, SEOV, or DOBV. Alternatively, it can be combined with the optimized PUUV DNA vaccine to protect against HFRS caused by any hantavirus.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: December 3, 2019
    Inventor: Connie Schmaljohn
  • Publication number: 20180280495
    Abstract: A synthetic, codon-optimized Hantaan virus (HTNV) full-length M gene open reading frame that consists of a unique nucleotide sequence encoding HTNV proteins. This synthetic gene was cloned into a plasmid to form the first optimized HTNV full-length M gene that elicits neutralizing antibodies in animals when delivered in combination with a similarly optimized Puumala virus (PUUV) DNA vaccine. The invention obviates the need for an extraneous gene sequence that was previously required for expression of the non-optimized HTNV gene. The synthetic gene is engineered into a molecular vaccine system to prevent hemorrhagic fever with renal syndrome (HFRS) caused by infection with HTNV, SEOV, or DOBV. Alternatively, it can be combined with the optimized PUUV DNA vaccine to protect against HFRS caused by any hantavirus.
    Type: Application
    Filed: April 5, 2018
    Publication date: October 4, 2018
    Applicant: Government of the United States, as represented by the Secretary of the Army
    Inventor: Connie Schmaljohn
  • Patent number: 9968669
    Abstract: A synthetic, codon-optimized Hantaan virus (HTNV) full-length M gene open reading frame that consists of a unique nucleotide sequence encoding HTNV proteins. This synthetic gene was cloned into a plasmid to form the first optimized HTNV full-length M gene that elicits neutralizing antibodies in animals when delivered in combination with a similarly optimized Puumala virus (PUUV) DNA vaccine. The invention obviates the need for an extraneous gene sequence that was previously required for expression of the non-optimized HTNV gene. The synthetic gene is engineered into a molecular vaccine system to prevent hemorrhagic fever with renal syndrome (HFRS) caused by infection with HTNV, SEOV, or DOBV. Alternatively, it can be combined with the optimized PUUV DNA vaccine to protect against HFRS caused by any hantavirus.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: May 15, 2018
    Assignee: The United States of America, as represented by the Secretary of the Army
    Inventor: Connie Schmaljohn
  • Patent number: 9675684
    Abstract: A synthetic, codon-optimized Hantaan virus (HTNV) full-length M gene open reading frame that consists of a unique nucleotide sequence encoding HTNV proteins. This synthetic gene was cloned into a plasmid to form the first optimized HTNV full-length M gene that elicits neutralizing antibodies in animals when delivered in combination with a similarly optimized Puumala virus (PUUV) DNA vaccine. The invention obviates the need for an extraneous gene sequence that was previously required for expression of the non-optimized HTNV gene. The synthetic gene is engineered into a molecular vaccine system to prevent hemorrhagic fever with renal syndrome (HFRS) caused by infection with HTNV, SEOV, or DOBV. Alternatively, it can be combined with the optimized PUUV DNA vaccine to protect against HFRS caused by any hantavirus.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: June 13, 2017
    Assignee: The United States of America as represented by The Secretary of The Army
    Inventor: Connie Schmaljohn
  • Publication number: 20170112916
    Abstract: A synthetic, codon-optimized Hantaan virus (HTNV) full-length M gene open reading frame that consists of a unique nucleotide sequence encoding HTNV proteins. This synthetic gene was cloned into a plasmid to form the first optimized HTNV full-length M gene that elicits neutralizing antibodies in animals when delivered in combination with a similarly optimized Puumala virus (PUUV) DNA vaccine. The invention obviates the need for an extraneous gene sequence that was previously required for expression of the non-optimized HTNV gene. The synthetic gene is engineered into a molecular vaccine system to prevent hemorrhagic fever with renal syndrome (HFRS) caused by infection with HTNV, SEOV, or DOBV. Alternatively, it can be combined with the optimized PUUV DNA vaccine to protect against HFRS caused by any hantavirus.
    Type: Application
    Filed: January 6, 2017
    Publication date: April 27, 2017
    Applicant: The Government of the Unites States as represented by the Secretary of the Army
    Inventor: Connie Schmaljohn
  • Patent number: 9556237
    Abstract: The invention entails synthetic short peptides based on Rift Valley Fever Virus (RVFV) fusion protein. The peptides are broad-spectrum antivirals, and are useful for prophylactic treatment against or therapeutic treatment of infection by hemorrhagic fever viruses, such as RVFV, Ebola Virus, and Andes Virus, as well as vesicular stomatitis virus.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: January 31, 2017
    Assignee: The United States of America, as represented by the Secretary of the Army, on behalf of the U.S. Army Medical Research Institute of Infectious Diseases
    Inventors: Connie Schmaljohn, Robert F. Garry, Jeffrey W. Koehler, Mary Guttieri
  • Patent number: 9446114
    Abstract: The invention relates to DNA vaccines that target multiple arenavirus agents singly or simultaneously.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: September 20, 2016
    Assignee: Inovio Pharmaceuticals, Inc.
    Inventors: Kate Broderick, Niranjan Sardesai, Kathleen Cashman, Connie Schmaljohn
  • Publication number: 20160051659
    Abstract: A synthetic, codon-optimized Hantaan virus (HTNV) full-length M gene open reading frame that consists of a unique nucleotide sequence encoding HTNV proteins. This synthetic gene was cloned into a plasmid to form the first optimized HTNV full-length M gene that elicits neutralizing antibodies in animals when delivered in combination with a similarly optimized Puumala virus (PUUV) DNA vaccine. The invention obviates the need for an extraneous gene sequence that was previously required for expression of the non-optimized HTNV gene. The synthetic gene is engineered into a molecular vaccine system to prevent hemorrhagic fever with renal syndrome (HFRS) caused by infection with HTNV, SEOV, or DOBV. Alternatively, it can be combined with the optimized PUUV DNA vaccine to protect against HFRS caused by any hantavirus.
    Type: Application
    Filed: September 24, 2015
    Publication date: February 25, 2016
    Inventor: Connie Schmaljohn
  • Publication number: 20150337015
    Abstract: The invention entails synthetic short peptides based on Rift Valley Fever Virus (RVFV) fusion protein. The peptides are broad-spectrum antivirals, and are useful for prophylactic treatment against or therapeutic treatment of infection by hemorrhagic fever viruses, such as RVFV, Ebola Virus, and Andes Virus, as well as vesicular stomatitis virus.
    Type: Application
    Filed: June 4, 2015
    Publication date: November 26, 2015
    Applicant: The United States of America, as represented by the Secretary of the Army, on behalf of the United
    Inventors: CONNIE SCHMALJOHN, Robert F. Garry, Jeffrey W. Koehler, Mary Guttieri
  • Publication number: 20050148529
    Abstract: Recombinant nucleic acid molecules are described. The molecules have a sequence or sequences encoding an antigen from Bacillus anthracis. Vectors and compositions containing these molecules are also described. Methods for eliciting an immune response using these molecules and compositions are also described.
    Type: Application
    Filed: January 5, 2004
    Publication date: July 7, 2005
    Applicant: Powderject Vaccines, Inc.
    Inventors: Connie Schmaljohn, James Fuller